Talphera (TLPH) Income towards Parent Company (2010 - 2026)
Talphera (TLPH) posted Income towards Parent Company of -$3.8 million for Q2 2026, up 0.71% on a QoQ basis from -$3.8 million in Q1 2026, and down 3.93% year-over-year from -$3.9 million in Q2 2025.
Analysis
Talphera (TLPH) Income towards Parent Company (2010 - 2026) Analysis & Trends
Talphera has reported Income towards Parent Company for 17 years, with the latest figure at -$3.8 million in Q2 2026.
- On a quarterly basis, Income towards Parent Company fell 3.93% year-over-year to -$3.8 million in Q2 2026; TTM through Jun 2026 was -$14.1 million, a 11.81% decrease from a year earlier, with the FY2025 full-year figure at -$13.0 million, up 10.97% from the prior year.
- Income towards Parent Company was -$3.8 million for Q2 2026 at Talphera, up from -$3.8 million in the prior quarter.
- The five-year high for Income towards Parent Company was $67.0 million in Q2 2022, with the low at -$13.4 million in Q1 2022.
- Average Income towards Parent Company over 5 years is $238944.4, with a median of -$3.5 million recorded in 2024.
- The largest YoY upside for Income towards Parent Company was 780.25% in 2022 against a maximum downside of 1316.97% in 2022.
- Over 5 years, Income towards Parent Company stood at -$7.7 million in 2022, then soared by 91.47% to -$655000.0 in 2023, then tumbled by 341.68% to -$2.9 million in 2024, then fell by 12.34% to -$3.2 million in 2025, then declined by 15.45% to -$3.8 million in 2026.
- The last three Income towards Parent Company figures came in at -$3.8 million (Q2 2026), -$3.8 million (Q1 2026), and -$3.2 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.58 Bn | 192.59 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.17 Bn | 176.99 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.59 Bn | 122.74 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.61 Bn | 73.61 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.24 Bn | 55.05 Bn | 1.37 Bn |
| 6 | Moderna | 54.29 Bn | 49.15 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 32.96 Bn | 29.65 Bn | 992.69 Mn |
| 8 | Biogen | 31.94 Bn | 30.66 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.38 Bn | 29.38 Bn | 1.16 Mn |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.75 Mn |
| Mar 31, 2026 | -3.78 Mn |
| Dec 31, 2025 | -3.25 Mn |
| Sep 30, 2025 | -3.34 Mn |
| Jun 30, 2025 | -3.61 Mn |
| Mar 31, 2025 | -2.77 Mn |
| Dec 31, 2024 | -2.89 Mn |
| Sep 30, 2024 | -3.35 Mn |
| Jun 30, 2024 | -3.83 Mn |
| Mar 31, 2024 | -4.02 Mn |
| Dec 31, 2023 | -655,000.00 |
| Sep 30, 2023 | -1.36 Mn |
| Jun 30, 2023 | -4.37 Mn |
| Mar 31, 2023 | 8.22 Mn |
| Dec 31, 2022 | -7.68 Mn |
| Sep 30, 2022 | -8.86 Mn |
| Jun 30, 2022 | 67.01 Mn |
| Mar 31, 2022 | -13.41 Mn |
| Dec 31, 2021 | -542,000.00 |
| Sep 30, 2021 | -8.38 Mn |